Repare RP-3500-01 (Advanced Solid Tumors) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out the safest and most effective dose of the study drug (RP-3500) is when given alone or in combination with talazoparib.

What is the Condition Being Studied?

Advanced solid tumors

Who Can Participate in the Study?

Adults with advanced cancer resistant to standard treatment with documented changes in certain genes.

Age Group
Adults

What is Involved?

If you choose to join this study you will:
-Go through a screening period to see if you qualify for the study
-Take the study drug (RP-3500) by mouth 1 or 2 times a day according to the assigned schedule
-Provide old tumor tissue
-Have physical exams, blood and urine tests
-Have imaging scans (CT and/or MRI)

Some people will also:
-Take talazoparib by mouth once daily
-Have tumor samples taken

Study Details

Full Title
Phase 1/2a Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-3500 Alone or in Combination with Talazoparib in Advanced Solid Tumors with ATR inhibitor Sensitizing Mutations (TRESR Study)
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00106181
NCT: NCT04497116
Phase
Phase I/II
ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698